Grandfield & Dodd LLC Increases Stock Position in Genmab A/S (NASDAQ:GMAB)

Grandfield & Dodd LLC increased its stake in shares of Genmab A/S (NASDAQ:GMAB) by 4.2% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 33,733 shares of the company’s stock after purchasing an additional 1,370 shares during the period. Grandfield & Dodd LLC’s holdings in Genmab A/S were worth $704,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in GMAB. GAMMA Investing LLC grew its position in Genmab A/S by 96.6% in the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock worth $45,000 after purchasing an additional 1,051 shares during the period. Cromwell Holdings LLC boosted its stake in shares of Genmab A/S by 656.8% in the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock worth $60,000 after buying an additional 2,496 shares during the last quarter. R Squared Ltd bought a new stake in shares of Genmab A/S in the fourth quarter worth $93,000. Allspring Global Investments Holdings LLC increased its position in Genmab A/S by 43.6% during the third quarter. Allspring Global Investments Holdings LLC now owns 4,653 shares of the company’s stock valued at $113,000 after acquiring an additional 1,413 shares during the last quarter. Finally, Blue Trust Inc. lifted its holdings in Genmab A/S by 33.4% in the fourth quarter. Blue Trust Inc. now owns 5,757 shares of the company’s stock valued at $120,000 after acquiring an additional 1,442 shares during the period. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Price Performance

Shares of GMAB opened at $22.67 on Monday. Genmab A/S has a 1 year low of $18.64 and a 1 year high of $31.88. The company has a 50 day simple moving average of $20.98 and a two-hundred day simple moving average of $22.75. The firm has a market cap of $15.00 billion, a P/E ratio of 13.03, a price-to-earnings-growth ratio of 2.65 and a beta of 0.96.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. On average, sell-side analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have issued reports on GMAB. BMO Capital Markets restated an “outperform” rating and set a $48.00 price target (up from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. BNP Paribas raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 11th. HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a research report on Thursday, January 23rd. Leerink Partnrs raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 13th. Finally, Leerink Partners raised Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price target for the company in a report on Thursday, February 13th. Four research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $42.17.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.